BofA/Merrill Lynch Starts Sarepta Therapeutic (SRPT) at Neutral

July 22, 2014 6:40 AM EDT
Get Alerts SRPT Hot Sheet
Price: $66.79 -3.36%

Rating Summary:
    26 Buy, 11 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 12 | New: 23
Trade Now! 
Join SI Premium – FREE

BofA/Merrill Lynch initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Neutral rating and a price target of $27.00.

Analyst Steve Byrne notes while there are several risks associated with eteplirsen, approval would boost the value of SRPT's pipeline of other DMD drugs. The firm DCF-derived PO of $27 is based on a 50% probability of approval, highlighting the binary outlook.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $21.57 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage